Taking people in GermanyNo phase
Studies adults with inflammatory diseases treated with biologic medicines
Follows adults with psoriasis, arthritis or bowel disease on biologic treatment.
Key facts
- Who runs it
- University Hospital Tuebingen
- Where
- Tübingen, GermanySee the site
- Trial code
- Registry title
- Molecular Inflammation Board at the Center for Personalized Medicine
- Status
- Recruiting
- People taking part
- 3,000 people, planned
- Started
- 16 Nov 2022
- Expected to end
- Nov 2032
- Type of study
- Observational
- Treatments tested
- Biologic Agent
- Record updated
- 20 August 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a long-lasting inflammatory disease: psoriasis, psoriatic arthritis, spondyloarthritis or inflammatory bowel disease.
- Age
- 18 years and older
- Sex
- Men and women can join.
- Disease stage
- Chronic inflammatory disease: psoriasis (PsO), psoriatic arthritis (PsA), spondyloarthritis (SpA) or inflammatory bowel disease (IBD).
Main reasons for not taking part
- People who cannot give consent
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Chronic inflammatory disorder (PsO, PsA, SpA, IBD)
- Given informed consent
- 18 years of age
Who cannot take part
- No capacity to consent
Where in Germany
- University Hospital of Tübingen - Center for Personalized MedicineTübingen, GermanyContact: Fee Schmitt, Dr.Taking people
About the trial
What the trial wants to find out
Molecular Inflammation Board at the Center for Personalized Medicine
Treatments tested
- Biologic Agent
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Molecular Inflammation Board at the Centers for Personalized Medicine at the University Hospitals of Freiburg, Heidelberg, Tübingen and Ulm - A Multicenter Prospective Observational Study
- Plain-language title
- Studies adults with inflammatory diseases treated with biologic medicinesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 20 August 2025